Verona Pharma to Present Seven Analyses of the Phase 3 ENHANCE Studies in COPD at ATS 2025
Analyses support Ohtuvayre® (ensifentrine) as a first-in-class selective dual
inhibitor of PDE3 and PDE4 for a broad COPD population
LONDON and RALEIGH, N.C., May 06, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) ('Verona' or the 'Company'), a biopharmaceutical company focused on respiratory diseases, announces ten posters including seven additional analyses from its Phase 3 ENHANCE studies with Ohtuvayre (ensifentrine) for the treatment of chronic obstructive pulmonary disease ('COPD'), two from nonclinical studies, and one from a real-world data analysis, will be presented at the American Thoracic Society Conference ('ATS') 2025. The posters are published on the ATS website and in the publication, American Journal of Respiratory and Critical Care Medicine.
Ohtuvayre is a first-in-class selective dual inhibitor of the enzymes phosphodiesterase 3 and 4 ('PDE3 and PDE4') that combines bronchodilator and non-steroidal anti-inflammatory effects in one molecule. Ohtuvayre is the first novel inhaled mechanism for the maintenance treatment of COPD in more than 20 years.
The ENHANCE posters highlight subgroup analyses of patients when used as monotherapy, in patients with COPD and comorbid cardiac disorders and, separately, in patients with COPD and comorbid type 2 diabetes. An analysis of Ohtuvayre's effect on COPD exacerbations relative to lung function results will also be presented. Nonclinical posters describe a tissue distribution study in rat demonstrating lack of brain exposure, and a bleomycin model in rat demonstrating antifibrotic effects following inhaled ensifentrine dosing. In addition, the Company will have an exhibition booth, 2237, which will host presentations led by clinical experts.
Details of Verona's posters are listed below and linked to the ATS website.
Poster P275: Ensifentrine Monotherapy Improved Lung Function and Reduced Exacerbation Rate and Risk in Symptomatic Patients With Moderate-to-Severe COPD
Presenter: Isaac Biney, MBChB, University of Tennessee Medical Center
Session: B52 – Hot Topics in COPD
Poster P283: Ensifentrine Improved Lung Function and Reduced Exacerbation Rate in Patients with COPD and Concomitant Type 2 Diabetes
Presenter: Matthew Moll, MD, Brigham and Women's Hospital
Session: B52 – Hot Topics in COPD
Poster P284: Ensifentrine Improved Lung Function and Reduced Exacerbations in Patients with COPD and Concomitant Cardiac Disorders
Presenter: Nirupama Putcha, MD, Johns Hopkins University
Session: B52 – Hot Topics in COPD
Poster P285: Ensifentrine Monotherapy Reduced Dyspnea and Improved Quality of Life in Patients With Symptomatic, Moderate-to-Severe COPD
Presenter: Michael Bradley Drummond, MD, University of North Carolina at Chapel Hill
Session: B52 – Hot Topics in COPD
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
17 minutes ago
- Yahoo
Liverpool get big Alexander Isak deal boost
There has been a DRAMATIC update in Liverpool's chase for Alexander Isak. On Tuesday the Newcastle forward took the unprecedented step of releasing a public statement over his current situation. 🚨2025/26 LFC x adidas range🚨 LFC x adidas Shop the home range today! LFC x adidas Shop the goalkeeper range today LFC x adidas Shop the new adidas range today! Isak, 25, claims promises have been broken by the Geordies and his current stance is that he will not play for the club again. 🔴 Shop the LFC 2025/26 adidas away range Liverpool tested Newcastle's resolve a few weeks back - offering a British record fee for the Swede - but the North East side were in no mood for negotiations. Newcastle make hefty Isak demands Despite Isak effectively being on strike it looks like the Magpies currently have no plans to sell him. Unless their demands are met - and more significantly unless they get two players into their strike line - then Liverpool could well be frustrated. Isak signed for Newcastle from Real Sociedad back in 2022 for a fee of £63m - agreeing a six-year contract - but relations with the club are at an all-time low. However, he will not be leaving for anyone else other than Liverpool. That's according to a new report in Caught Offside - which also reveals that Newcastle would deal at £147m. Isak is pushing hard for Liverpool 'Figures close to the situation described Isak as 'pushing hard' to get his dream transfer to LFC, who remain in 'pole position' to capitalise on this dire situation with Newcastle,' the report reads. 'So far, the Premier League champions have had a £110m bid rejected by NUFC, who are adamant that their asking price of around £147m must be met.' There have been links with Al-Hilal - and more outlandishly with Real Madrid - but it appears Isak has got eyes only for the Premier League champions. © IMAGO - Alexander Isak Liverpool
Yahoo
17 minutes ago
- Yahoo
Army spends £118m on more systems to shoot down missiles and drones
The Army has bought more air defence missile systems with the capability to shoot down cruise missiles and drones, the Ministry of Defence has said. The £118 million move will double the number of British-made Land Ceptor systems available to the British Army. It said they could be deployed both in the UK and overseas. The new equipment will form part of Sky Sabre, a state-of-the-art defence system that can intercept munitions and aircraft. It replaced the previous Rapier system, which had run since the 1970s. The MRAD (medium range air defence) system will be made by manufacturer MBDA in Bolton. The Government said 140 jobs will be supported by the move. Defence minister Luke Pollard said: 'We are delivering on the strategic defence review by equipping our armed forces with state-of-the art equipment to help keep us safe. Doubling our deployable Sky Sabre capability will strengthen the UK's air defences, protect UK forces abroad, and deter our adversaries. 'Through this investment we are supporting over 100 jobs across the UK, with more to come.' The Land Ceptor systems are able to hit a tennis-ball sized object which is travelling at twice the speed of sound. The Sky Sabre operation can control 24 missiles at one time. As part of the system, the Land Ceptors operate alongside radar and a wider command and control centre. However, they are also able to be used on their own. Sky Sabre was recently tested as part of a Nato exercise in the Outer Hebrides, the Ministry of Defence said. It has already been deployed in Poland, as part of Nato operations with on eye on Russia. Commanding Officer of the 16th Regiment Royal Artillery, Lt Col James Boutle, said: 'Sky Sabre represents a step change in the UK's ground-based air defence capability. 'As the Army's most advanced air defence system, it provides a powerful shield against modern airborne threats, from fast jets to precision-guided weapons and drones. 'For 16th Regiment Royal Artillery, operating Sky Sabre is both a privilege and a responsibility – ensuring we are trained and ready to strengthen the UK's contribution to Nato when called upon. 'As part of this, we work hand-in-hand with industry partners, such as MBDA here in the UK, to continuously optimise the system to ensure it remains on the cutting edge – a collaboration that guarantees we stay ahead of adversary technology.'
Bloomberg
20 minutes ago
- Bloomberg
UK Expands Air Defenses as Europe Wakes Up to Missile Gap
The UK is bolstering its air defense capabilities with a new contract for missile systems, as European military planners work to map out a post-peace plan for Ukraine that could see its skies protected by western allies. In a deal worth £118 million ($159 million), the British government will buy six new Land Ceptor systems from multinational European arms maker MBDA over three years, the Ministry of Defence said Thursday in a statement. They comprise so-called anti-air modular missiles capable of hitting a tennis-ball sized object traveling at twice the speed of sound, as well as launchers and support vehicles.
